Possible role of EMID2 on nasal polyps pathogenesis in Korean asthma patients

BMC Medical Genetics

Table 4 Association of significant EMID2 variants with nasal polyps in ATA patients (n = 353)

SNP/Haplotype	MAF		Co-dominant			Dominant			Recessive
	Polyp-positive (n = 92)	Polyp-negative (n = 261)	OR(95%CI)	P*	P ^corr **	OR(95%CI)	P*	P ^corr **	OR(95%CI)	P*	P ^corr **
rs6947185C > A	0.457	0.538	0.72(0.51-1.01)	0.06	-	0.86(0.50-1.50)	0.60	-	0.46(0.25-0.84)	0.01	NS
rs12538381C > T	0.109	0.094	1.18(0.69-2.05)	0.55	-	1.01(0.55-1.86)	0.99	-	10.96(1.08-111.20)	0.04	NS
rs17135512A > G	0.109	0.094	1.18(0.69-2.05)	0.55	-	1.01(0.55-1.86)	0.99	-	10.96(1.08-111.20)	0.04	NS
rs13245946C > T	0.125	0.069	1.85(1.08-3.16)	0.02	NS	1.69(0.91-3.14)	0.10	-	13.43(1.44-125.46)	0.02	NS
EMID2_BL1_ht2	0.196	0.284	0.61(0.41-0.93)	0.02	NS	0.65(0.39-1.06)	0.08	-	0.20(0.05-0.88)	0.03	NS
EMID2_BL4_ht1	0.266	0.201	1.42(0.96-2.09)	0.08	-	2.68(1.05-6.85)	0.04	NS	1.34(0.83-2.18)	0.24	-

*P-values at 0.05 level of significance adjusted for initial diagnosed age, sex, smoking status, and atopy. Significant values are shown in bold.
**P-values after multiple testing corrections (Meff = 42.7377).
MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; NS, not significant.

ISSN: 1471-2350